Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 29;3(3):CD011523.
doi: 10.1002/14651858.CD011523.pub2.

Medical versus surgical treatment for refractory or recurrent peptic ulcer

Kurinchi Selvan Gurusamy  1 , Elena Pallari
Affiliations

Medical versus surgical treatment for refractory or recurrent peptic ulcer

Kurinchi Selvan Gurusamy et al. Cochrane Database Syst Rev. .

Abstract

Background: Refractory peptic ulcers are ulcers in the stomach or duodenum that do not heal after eight to 12 weeks of medical treatment or those that are associated with complications despite medical treatment. Recurrent peptic ulcers are peptic ulcers that recur after healing of the ulcer. Given the number of deaths due to peptic ulcer-related complications and the long-term complications of medical treatment (increased incidence of fracture), it is unclear whether medical or surgical intervention is the better treatment option in people with recurrent or refractory peptic ulcers.

Objectives: To assess the benefits and harms of medical versus surgical treatment for people with recurrent or refractory peptic ulcer.

Search methods: We searched the specialised register of the Cochrane Upper GI and Pancreatic Diseases group, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and trials registers until September 2015 to identify randomised trials and non-randomised studies, using search strategies. We also searched the references of included studies to identify further studies.

Selection criteria: We considered randomised controlled trials and non-randomised studies comparing medical treatment with surgical treatment in people with refractory or recurrent peptic ulcer, irrespective of language, blinding, or publication status for inclusion in the review.

Data collection and analysis: Two review authors independently identified trials and extracted data. We planned to calculate the risk ratio, mean difference, standardised mean difference, or hazard ratio with 95% confidence intervals using both fixed-effect and random-effects models with Review Manager 5 based on intention-to-treat analysis.

Main results: We included only one non-randomised study published 30 years ago in the review. This study included 77 participants who had gastric ulcer and in whom medical therapy (histamine H2 receptor blockers, antacids, and diet) had failed after an average duration of treatment of 29 months. The authors do not state whether these were recurrent or refractory ulcers. It appears that the participants did not have previous complications such as bleeding or perforation. Of the 77 included participants, 37 participants continued to have medical therapy while 40 participants received surgical therapy (antrectomy with or without vagotomy; subtotal gastrectomy with or without vagotomy; vagotomy; pyloroplasty and suture of the ulcer; suture or closure of ulcer without vagotomy or excision of the ulcer; proximal gastric or parietal cell vagotomy alone; suture or closure of the ulcer with proximal gastric or parietal cell vagotomy). Whether to use medical or surgical treatment was determined by participant's or treating physician's preference.The study authors reported that two participants in the medical treatment group (2 out of 37; 5.4%) had gastric cancer, which was identified by repeated biopsy. They did not report the proportion of participants who had gastric cancer in the surgical treatment group. They also did not report the implications of the delayed diagnosis of gastric cancer in the medical treatment group. They did not report any other outcomes of interest for this review (that is health-related quality of life (using any validated scale), adverse events and serious adverse events, peptic ulcer bleeding, peptic ulcer perforation, abdominal pain, and long-term mortality).

Authors' conclusions: We found no studies that provide the relative benefits and harms of medical versus surgical treatment for recurrent or refractory peptic ulcers. Studies that evaluate the natural history of recurrent and refractory peptic ulcers are urgently required to determine whether randomised controlled trials comparing medical versus surgical management in patients with recurrent or refractory peptic ulcers or both are necessary. Such studies will also provide information for the design of such randomised controlled trials. A minimum follow-up of two to three years will allow the calculation of the incidence of complications and gastric cancer (in gastric ulcers only) in recurrent and refractory peptic ulcers. In addition to complications related to treatment and disease, health-related quality of life and loss of productivity should also be measured.

PubMed Disclaimer

Conflict of interest statement

This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 ‐ Evidence‐based diagnosis and management of upper digestive, hepato‐biliary, and pancreatic disorders). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.

KSG: none known.

EP: none known.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Adkins 1985 {published data only}
    1. Adkins RB Jr, DeLozier JB 3rd, Scott HW Jr, Sawyers JL. The management of gastric ulcers. A current review. Annals of Surgery 1985;201(6):741‐51. - PMC - PubMed

References to studies excluded from this review

Amdrup 1981 {published data only}
    1. Amdrup E. Recurrent ulcer. British Journal of Surgery 1981;68(10):679‐81. - PubMed
Anonymous 1981 {published data only}
    1. Anonymous. Surgical vagotomy should as a rule be preferred to cimetidine in the treatment of recurrent duodenal ulcer. Lakartidningen 1981;78(19):1062. - PubMed
Bardhan 2003 {published data only}
    1. Bardhan KD, Nayyar AK, Royston C. History in our lifetime: The changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. Digestive and Liver Disease 2003;35(8):529‐36. - PubMed
Barragry 1986 {published data only}
    1. Barragry TP, Blatchford JW 3rd, Allen MO. Giant gastric ulcers. A review of 49 cases. Annals of Surgery 1986;203(3):255‐9. - PMC - PubMed
Bouillot 1991 {published data only}
    1. Bouillot JL, Chenebaux D, Bloch F, Gripon S, Loulidi S, Petite JP, et al. Hemorrhagic gastro‐duodenal ulcers. In which cases should emergency surgery be performed?. Annales de Chirurgie 1991;45(10):877‐81. - PubMed
Brehant 2008 {published data only}
    1. Brehant O, Duval H, Dumont F, Fuks D, Deshpande S, Verhaeghe P, et al. Surgical conservative treatment of recurrent bleeding duodenal ulcer. Hepato‐Gastroenterology 2008;55(85):1327‐31. - PubMed
Chung 1998 {published data only}
    1. Chung HC, Lo SS, Wu CW, Hsieh MC, Lui WY. Management strategies of marginal ulcers. Journal of Surgical Association Republic of China 1998;31(2):103‐8.
De Vernejoul 1947 {published data only}
    1. Vernejoul R. Total gastrectomy for recurrent peptic ulcer. Bulletins et Memoires de la Societe de Chirurgie de Marseille 1947;20(3‐4):101‐2.
Harling 1985 {published data only}
    1. Harling H, Balslev I, Bentzen E. Parietal cell vagotomy or cimetidine maintenance therapy for duodenal ulcer? A prospective controlled trial. Scandinavian Journal of Gastroenterology 1985;20(6):747‐50. - PubMed
Kinney 1988 {published data only}
    1. Kinney E, Goderwis D, Mullins RJ, Larson GM. Management of recurrent duodenal ulcer disease. American Surgeon 1988;54(1):15‐8. - PubMed
Koo 1982 {published data only}
    1. Koo J, Lam SK, Ong GB. Cimetidine versus surgery for recurrent ulcer after gastric surgery. Annals of Surgery 1982;195(4):406‐12. - PMC - PubMed
    1. Lam SK, Koo J, Ong GB. Cimetidine versus surgery for recurrent ulcer after gastric surgery. Gut 1981;22(10):F21. - PMC - PubMed
Lindenauer 1975 {published data only}
    1. Lindenauer SM, Dent TL. Management of the recurrent ulcer. Archives of Surgery 1975;110(5):531‐6. - PubMed
Mandache 1971 {published data only}
    1. Mandache F, Vasiliu M. Surgical approach in upper gastrointestinal hemorrhages from gastroduodenal ulcer. Chir 1971;20(6):27‐30.
Neustein 1976 {published data only}
    1. Neustein CL, Bushkin FL, Woodward ER. Recurrent peptic ulceration. Major Problems in Clinical Surgery 1976;20:83‐91. - PubMed
Nguyen 2007 {published data only}
    1. Nguyen NT, Hinojosa MW, Gray J, Fayad C. Reoperation for marginal ulceration. Surgical Endoscopy 2007;21(11):1919‐21. - PubMed

Additional references

Ahsberg 2011
    1. Ahsberg K, Ye W, Lu Y, Zheng Z, Stael von Holstein C. Hospitalisation of and mortality from bleeding peptic ulcer in Sweden: a nationwide time‐trend analysis. Alimentary Pharmacology and Therapeutics 2011;33(5):578‐84. - PubMed
ASGE Standards of Practice Committee 2010
    1. ASGE Standards of Practice Committee, Banerjee S, Cash BD, Dominitz JA, Baron TH, Anderson MA, Ben‐Menachem T, et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointestinal Endoscopy 2010;71(4):663‐8. - PubMed
Barksdale 2002
    1. Barksdale AR, Schwartz RW. The evolving management of gastric outlet obstruction from peptic ulcer disease. Current Surgery 2002;59(4):404‐9. - PubMed
Barkun 2010
    1. Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. American Journal of Medicine 2010;123(4):358‐66 e2. - PubMed
Beggs 2014
    1. Beggs AD, Dilworth MP, Powell SL, Atherton H, Griffiths EA. A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clinical and Experimental Gastroenterology 2014;7:93‐104. - PMC - PubMed
Bertleff 2010
    1. Bertleff MJ, Lange JF. Perforated peptic ulcer disease: a review of history and treatment. Digestive Surgery 2010;27(3):161‐9. - PubMed
Breslin 1999
    1. Breslin NP, Sutherland LR. Survey of current practices among members of CAG in the follow‐up of patients diagnosed with gastric ulcer. Canadian Journal of Gastroenterology 1999;13(6):489‐93. - PubMed
Bustamante 2002
    1. Bustamante M, Devesa F, Borghol A, Ortuno J, Ferrando MJ. Accuracy of the initial endoscopic diagnosis in the discrimination of gastric ulcers: Is endoscopic follow‐up study always needed?. Journal of Clinical Gastroenterology 2002;35(1):25‐8. - PubMed
Coblijn 2014
    1. Coblijn UK, Goucham AB, Lagarde SM, Kuiken SD, Wagensveld BA. Development of ulcer disease after Roux‐en‐Y gastric bypass, incidence, risk factors, and patient presentation: A systematic review. Obesity Surgery 2014;24(2):299‐309. - PubMed
Csendes 2009
    1. Csendes A, Burgos AM, Smok G, Burdiles P, Braghetto I, Diaz JC. Latest results (12‐21 years) of a prospective randomized study comparing Billroth II and Roux‐en‐Y anastomosis after a partial gastrectomy plus vagotomy in patients with duodenal ulcers. Annals of Surgery 2009;249(2):189‐94. - PubMed
de Vries 2008
    1. Vries AC, Grieken NC, Looman CW, Casparie MK, Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008;134(4):945‐52. - PubMed
Demets 1987
    1. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Eckardt 1992
    1. Eckardt VF, Giessler W, Kanzler G, Bernhard G. Does endoscopic follow‐up improve the outcome of patients with benign gastric ulcers and gastric cancer?. Cancer 1992;69(2):301‐5. - PubMed
Edholm 2015
    1. Edholm D, Ottosson J, Sundbom M. Importance of pouch size in laparoscopic Roux‐en‐Y gastric bypass: A cohort study of 14,168 patients. Surgical Endoscopy 2015;[Epub ahead of print]:1‐5. [DOI: 10.1007/s00464-015-4432-2] - DOI - PubMed
Egger 1997
    1. Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
FDA 2006
    1. Center for Biologics Evaluation and Research, US Food, Drug Administration. Guidance for industry adverse reactions section of labeling for human prescription drug and biological products ‐ Content and format. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati... 2006 (accessed on 4 July 2014).
Ford 2008
    1. Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Digestive Diseases 2008;26(3):225‐30. - PubMed
Gielisse 2015
    1. Gielisse EA, Kuyvenhoven JP. Follow‐up endoscopy for benign‐appearing gastric ulcers has no additive value in detecting malignancy: It is time to individualise surveillance endoscopy. Gastric Cancer 2015;18(4):803‐9. - PubMed
Griffiths 2013
    1. Griffiths EA, Devitt PG, Bright T, Watson DI, Thompson SK. Surgical management of peptic ulcer bleeding by Australian and New Zealand upper gastrointestinal surgeons. ANZ Journal of Surgery 2013;83(3):104‐8. - PubMed
Hermansson 2009
    1. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974‐2002. BMC Gastroenterology 2009;9:25. - PMC - PubMed
Hernandez‐Diaz 2013
    1. Hernandez‐Diaz S, Martin‐Merino E, Garcia Rodriguez LA. Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Digestive Diseases and Sciences 2013;58(6):1653‐62. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane‐handbook.org.
Hopper 2006
    1. Hopper AN, Stephens MR, Lewis WG, Blackshaw GR, Morgan MA, Thompson I, et al. Relative value of repeat gastric ulcer surveillance gastroscopy in diagnosing gastric cancer. Gastric Cancer 2006;9(3):217‐22. - PubMed
Hosokawa 2001
    1. Hosokawa O, Watanabe K, Hatorri M, Douden K, Hayashi H, Kaizaki Y. Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy 2001;33(4):301‐5. - PubMed
Huang 2002
    1. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non‐steroidal anti‐inflammatory drugs in peptic‐ulcer disease: a meta‐analysis. The Lancet 2002;359(9300):14‐22. - PubMed
Hunter 2012
    1. Hunter J, Stahl RD, Kakade M, Breitman I, Grams J, Clements RH. Effectiveness of thoracoscopic truncal vagotomy in the treatment of marginal ulcers after laparoscopic Roux‐en‐Y gastric bypass. American Surgeon 2012;78(6):663‐8. - PubMed
ICH‐GCP 1996
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1996.
Ikenberry 2007
    1. Ikenberry SO, Harrison ME, Lichtenstein D, Dominitz JA, Anderson MA, Jagannath SB, et al. The role of endoscopy in dyspepsia. Gastrointestinal Endoscopy 2007;66(6):1071‐5. - PubMed
Johnson 1965
    1. Johnson HD. Gastric ulcer: classification, blood group characteristics, secretion patterns and pathogenesis. Annals of Surgery 1965;162(6):996‐1004. - PMC - PubMed
Katz 2010
    1. Katz PO, Zavala S. Proton pump inhibitors in the management of GERD. Journal of Gastrointestinal Surgery 2010;14 Suppl 1:S62‐6. - PubMed
Kurata 1997
    1. Kurata JH, Nogawa AN. Meta‐analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. Journal of Clinical Gastroenterology 1997;24(1):2‐17. - PubMed
Lagoo 2014
    1. Lagoo J, Pappas TN, Perez A. A relic or still relevant: the narrowing role for vagotomy in the treatment of peptic ulcer disease. American Journal of Surgery 2014;207(1):120‐6. - PubMed
Lau 2011
    1. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011;84(2):102‐13. - PubMed
Lau 2013
    1. Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. The Lancet 2013;381(9882):2033‐43. - PubMed
Lin 2011
    1. Lin KJ, Garcia Rodriguez LA, Hernandez‐Diaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?. Pharmacoepidemiology and Drug Safety 2011;20(7):718‐28. - PubMed
Malfertheiner 2009
    1. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. The Lancet 2009;374(9699):1449‐61. - PubMed
Malfertheiner 2011
    1. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Digestive Diseases 2011;29(5):459‐64. - PubMed
Malfertheiner 2012
    1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection ‐ the Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646‐64. - PubMed
Malmi 2014
    1. Malmi H, Kautiainen H, Virta LJ, Farkkila N, Koskenpato J, Farkkila MA. Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Alimentary Pharmacology and Therapeutics 2014;39(5):496‐506. - PubMed
Manas 2009
    1. Manas MD, Domper A, Albillos A, Hernandez A, Carpintero P, Lorente R, et al. Endoscopic follow‐up of gastric ulcer in a population at intermediate risk for gastric cancer. Revista Española de Enfermedades Digestivas 2009;101(5):317‐24. - PubMed
Manuel 2007
    1. Manuel D, Cutler A, Goldstein J, Fennerty MB, Brown K. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease‐related complications. Alimentary Pharmacology and Therapeutics 2007;25(12):1423‐7. - PubMed
Martindale 2011
    1. Sweetman S (editor). Martindale: the complete drug reference (online version), 37th edition. www.pharmpress.com/product/MC_MART/martindale‐the‐complete‐drug‐reference 2011 (accessed 23 September 2014).
MHRA 2013
    1. Medicines and Healthcare products Regulatory Agency (MHRA). Clinical trials for medicines: Safety reporting ‐ SUSARs and DSURs. http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clin... 2013 (accessed 4 July 2014).
Moller 2013
    1. Moller MH, Vester‐Andersen M, Thomsen RW. Long‐term mortality following peptic ulcer perforation in the PULP trial. A nationwide follow‐up study. Scandinavian Journal of Gastroenterology 2013;48(2):168‐75. - PubMed
Napolitano 2009
    1. Napolitano L. Refractory peptic ulcer disease. Gastroenterology Clinics of North America 2009;38(2):267‐88. - PubMed
Neumann 2013
    1. Neumann I, Letelier LM, Rada G, Claro JC, Martin J, Howden CW, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD007999.pub2] - DOI - PMC - PubMed
NICE 2014
    1. National Clinical Guideline Centre. Obesity. Identification, assessment and management of overweight and obesity in children, young people and adults. http://www.nice.org.uk/guidance/cg189/evidence/obesity‐update‐full‐guide... 2014 (accessed 25 November 2015).
Palanivelu 2006
    1. Palanivelu C, Jani K, Rajan PS, Kumar KS, Madhankumar MV, Kavalakat A. Laparoscopic management of acid peptic disease. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2006;16(5):312‐6. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Peek 1997
    1. Peek RM, Jr, Blaser MJ. Pathophysiology of Helicobacter pylori‐induced gastritis and peptic ulcer disease. American Journal of Medicine 1997;102(2):200‐7. - PubMed
Peery 2012
    1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143(5):1179‐87 e1‐3. - PMC - PubMed
Podolsky 1988
    1. Podolsky I, Storms PR, Richardson CT, Peterson WL, Fordtran JS. Gastric adenocarcinoma masquerading endoscopically as benign gastric ulcer. A five‐year experience. Digestive Diseases and Sciences 1988;33(9):1057‐63. - PubMed
Post 2006
    1. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nationwide study in the Netherlands. Alimentary Pharmacology and Therapeutics 2006;23(11):1587‐93. - PubMed
Review Manager 2014 [Computer program]
    1. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.
Sandler 2002
    1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122(5):1500‐11. - PubMed
Shaheen 2006
    1. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. American Journal of Gastroenterology 2006;101(9):2128‐38. - PubMed
Sterne 2014
    1. Sterne JAC, Higgins JPT, Reeves BC on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomized Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0. http://www.riskofbias.info (accessed 25 November 2015).
Sung 2009
    1. Sung JJ, Kuipers EJ, El‐Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary Pharmacology and Therapeutics 2009;29(9):938‐46. - PubMed
Thorsen 2013
    1. Thorsen K, Soreide JA, Kvaloy JT, Glomsaker T, Soreide K. Epidemiology of perforated peptic ulcer: age‐ and gender‐adjusted analysis of incidence and mortality. World Journal of Gastroenterology 2013;19(3):347‐54. - PMC - PubMed
Vesely 1968
    1. Vesely KT, Kubickova Z, Dvorakova M. Clinical data and characteristics differentiating types of peptic ulcer. Gut 1968;9(1):57‐68. - PMC - PubMed
Welage 2003
    1. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003;23(10 Pt 2):74S‐80S. - PubMed
Yu 2011
    1. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta‐analysis of 11 international studies. American Journal of Medicine 2011;124(6):519‐26. - PMC - PubMed
Zittel 2000
    1. Zittel TT, Jehle EC, Becker HD. Surgical management of peptic ulcer disease today ‐ indication, technique and outcome. Langenbecks Archives of Surgery 2000;385(2):84‐96. - PubMed

Publication types

LinkOut - more resources